Method for treating liver cirrhosis using mesenchymal stem cell composition
Summary
The USPTO granted patent US12594304B2 to GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD. for a method of treating liver cirrhosis using a composition comprising mesenchymal stem cells, extracellular vesicles produced by mesenchymal stem cells, and growth factors. The patent contains 15 claims and is classified under CPC codes A61K 35/28, A61K 9/0019, and A61P 1/16.
What changed
The USPTO issued patent US12594304B2 granting exclusive rights to GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD. for a method of treating liver cirrhosis using a composition including mesenchymal stem cells, extracellular vesicles, and growth factors. The filing date was October 4, 2023, with the patent issued on April 7, 2026.
For pharmaceutical and biotech companies, this patent establishes intellectual property protection for stem cell-based liver cirrhosis treatments in the United States. Competitors developing similar mesenchymal stem cell therapies for liver disease will need to either license this technology or design around the granted claims. Research institutions and drug developers should conduct freedom-to-operate analyses before commencing clinical development programs in this therapeutic area.
What to do next
- Monitor patent scope and validity period
- Assess licensing opportunities for stem cell-based liver cirrhosis treatments
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method for treating liver cirrhosis by using composition comprising mesenchymal stem cell. extracellular vesicle produced by mesenchymal stem cell, and growth factor
Grant US12594304B2 Kind: B2 Apr 07, 2026
Assignee
GWO XI STEM CELL APPLIED TECHNOLOGY CO., LTD.
Inventors
Po-Cheng Lin, Pi-Chun Huang, Zih-Han Hong, Ming-Hsi Chuang, Yi-Chun Lin, Chia-Hsin Lee, Chun-Hung Chen, Chao-Liang Chang, Kai-Ling Zhang
Abstract
The present disclosure provides a method for treating liver cirrhosis by using a composition including mesenchymal stem cells, extracellular vesicles produced by the mesenchymal stem cells, and growth factors. The composition of the present disclosure achieves the effect of treating liver cirrhosis through various efficacy experiments.
CPC Classifications
A61K 35/28 A61K 9/0019 A61P 1/16
Filing Date
2023-10-04
Application No.
18376545
Claims
15
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.